An interventional study of Conjuran and Hyruan in Knee Osteoarthritis, sponsored by PharmaResearch Co.,Ltd. Not yet recruiting. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-06-12.
Sponsored by PharmaResearch Co.,Ltd · Not applicable, Interventional, and Treatment
This clinical trial aims to evaluate and compare the efficacy and safety of Conjuran® and Hyruan in patients with knee osteoarthritis following first and second cycle (repeat) administration.
3,302 studies on the registry are indexed under Osteoarthritis, Knee; 608 are open to participants now.
This study's planned enrollment of 180 is above the median of 70 across 2,731 interventional studies indexed under Osteoarthritis, Knee.
Browse Osteoarthritis, Knee studies →PharmaResearch Co.,Ltd is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Once a week for 5 injections
Device: Conjuran
Once a week for 5 injections
Drug: Hyruan
Once a week for 5 injections
Also known as: Polynucleotide sodium (PN)
Once a week for 5 injections
Also known as: Sodium Hyaluronate
Weight-Bearing Pain (WBP) Visual Analog Scale (VAS)
Change from baseline in WBP after the first treatment assessed using a 100-mm Visual Analog Scale (VAS), ranging from 0 to 100. Higher scores indicate worse pain
Time frame: Week 16
Weight-Bearing Pain (WBP), Resting Pain (RP), and Motion Pain (MP) VAS
Change from baseline in WBP, RP, and MP after the first and second treatment cycles, assessed using a 100-mm VAS (0-100). Higher scores indicate worse pain.
Time frame: Up to 56 weeks
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Score
Change from baseline in WOMAC total and subscale scores after the first and second treatment cycles. WOMAC is a 24-item questionnaire with scores ranging from 0 to 96. Higher scores indicate worse symptoms.
Time frame: Up to 56 weeks
EQ-5D (EuroQol 5-Dimension Health Questionnaire)
Change from baseline in EQ-5D score after the first and second treatment cycles. EQ-5D consists of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and an EQ Visual Analog Scale (EQ VAS; 0-100). Higher scores indicate better health status.
Time frame: Up to 56 weeks
Patient Global Assessment (PGA), Investigator Global Assessment (IGA)
Change from baseline in PGA and IGA after the first and second treatment cycles, assessed using a 100-mm Visual Analog Scale (VAS) (0-100). Higher scores indicate worse disease status.
Time frame: Up to 56 weeks
WBP and OMERACT-OARSI Responder Rate
Proportion of participants meeting WBP responder criteria or OMERACT-OARSI responder criteria
Time frame: Up to 56 weeks
Rescue Medication Use
Proportion (%) of participants using rescue medication and amount of rescue medication consumed.
Time frame: Up to 56 weeks
Incidence of Adverse Events, Laboratory Abnormalities, Vital Sign Abnormalities, and Physical Examination Findings [Safety Evaluation]
Incidence of adverse events, local adverse events, laboratory abnormalities, vital sign abnormalities, and physical examination findings.
Time frame: Up to 56 weeks
No study locations are listed for this record.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
PharmaResearch Co.,Ltd